

JAN. 23. 2008 1:46PM

919-854-1401 MBS&S

RECEIVED  
CENTRAL FAX CENTER  
NO. 6711

1AP12 Rec'd PCT/PTO 23 JAN 2008 JAN 23 2008

Attorney Docket No. 9052-212

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Rowlands et al.  
Application No.: 10/520,550  
Filed: May 17, 2006  
For: **USE OF HEPATITIS C VIRUS (HCV) P7 PROTEIN**

Confirmation No.: 3251  
Group Art Unit No.: 1648  
Examiner: Michelle S. Horning

Date: January 23, 2008

Mail Stop PGPub  
Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

REQUESTED FOR CORRECTED PUBLICATION UNDER 37 CFR 1.221(B)


Sir:

In reviewing the Patent Application Publication (see first page of Publication) for the above referenced application, Applicants noted errors that Applicants believe may be considered material to the application. Specifically, Applicant notes that the inventors names incorrectly appear as David Rowlands, Leeds (GB), Shawn Cannon Lemon, Leeds (GB), and Syephen Griffin, Leeds (GB). These errors were apparently made by the PTO (see attached copy of originally filed application transmittal and first page of PCT Publication WO 2004/005333A1).

Applicants respectfully request that the inventors be corrected to read **David Rowlands, Leeds (GB) and Stephen Griffin, Leeds (GB)**.

Applicants respectfully request that the errors be corrected and that a corrected Patent Application Publication be issued. Applicants believe that there should be no fee for this correction.


Respectfully Submitted,

  
Shawna Cannon Lemon  
Registration No.: 53,888

Myers Bigel Sibley & Sajovec, P.A.  
P. O. Box 37428  
Raleigh, North Carolina 27627  
Telephone: (919) 854-1400  
Facsimile: (919) 854-1401  
Customer No. 20792

**CERTIFICATION OF FACSIMILE  
TRANSMISSION  
UNDER 37 CFR § 1.8**

I hereby certify that this correspondence is being facsimile transmitted to the U.S. Patent and Trademark Office via facsimile number 571-273-8300 on January 23, 2008.

  
Betty Lou Rosser  
Date of Signature: January 23, 2008

JAN. 23. 2008 1:47PM

919-854-1401 MBS&S

NO. 6711 P. 2



US 20060252918A1

RECEIVED  
CENTRAL FAX CENTER

(19) **United States**

(12) **Patent Application Publication**  
**Rowlands et al.**

(10) Pub. No.: **US 2006/0252918A1**  
(43) Pub. Date: **Nov. 9, 2006**

(54) **USE OF HEPATITIS VIRUS (HCV) P7  
PROTEIN**

(30) **Foreign Application Priority Data**

Jul. 8, 2002 (GB)..... 0215617.2

(76) Inventors: **David Rowlands, Leeds (GB); Shawn  
Cannon Lemon, Leeds (GB); Syephen  
Griffin, Leeds (GB)**

**Publication Classification**

Correspondence Address:  
**MYERS BIGEL SIBLEY & SAJOVEC  
PO BOX 37428  
RALEIGH, NC 27627 (US)**

(51) Int. Cl.  
**C12Q 1/70 (2006.01)**  
**C07K 14/18 (2006.01)**  
(52) U.S. Cl. .... 530/350; 435/5

(21) Appl. No.: **10/520,550**



(57) **ABSTRACT**

(22) PCT Filed: **Jul. 7, 2003**

The present invention relates to the use of hepatitis C virus (HCV) p7 protein, and particularly but not exclusively, to its use in rationalised drug design and as a screen for antiviral therapeutic agents.

(86) PCT No.: **PCT/GB03/02937**

Form PTO-1390 (REV. 11-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		NEW DOCKET NUMBER 905. .12	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (if known, see 37 CFR 1.5) <b>RECEIVED</b> CENTRAL FAX CENTER	
INTERNATIONAL APPLICATION NO. PCT/GB2003/002937		INTERNATIONAL FILING DATE 7 July 2003		PRIORITY DATE CLAIMED 8 July 2002	
TITLE OF INVENTION USE OF HEPATITIS C VIRUS (HCV) P7 PROTEIN					
APPLICANT(S) FOR DO/EO/US ROWLANDS, David; GRIFFIN, Stephen					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
<ol style="list-style-type: none"> <li>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (22) indicated below.</li> <li>4. <input checked="" type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31).</li> <li>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input checked="" type="checkbox"/> has been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ol> </li> <li>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> is attached hereto.</li> <li>b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4)</li> </ol> </li> <li>7. <input type="checkbox"/> Amendments to the claims of the International Application Under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input type="checkbox"/> have been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li>d. <input type="checkbox"/> have not been made and will not be made.</li> </ol> </li> <li>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</li> <li>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</li> <li>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report Under PCT Article 36 (35 U.S.C. 371(c)(5)).</li> </ol>					
Items 11 to 21 below concern document(s) or information included:					
<ol style="list-style-type: none"> <li>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</li> <li>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</li> <li>13. <input checked="" type="checkbox"/> A <b>FIRST</b> preliminary amendment.</li> <li>14. <input type="checkbox"/> A <b>SECOND</b> or <b>SUBSEQUENT</b> preliminary amendment.</li> <li>15. <input type="checkbox"/> An Application Data Sheet Under 37 CFR 1.76.</li> <li>16. <input type="checkbox"/> A substitute specification.</li> <li>17. <input type="checkbox"/> A change of power of attorney and/or address letter.</li> <li>18. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.</li> <li>19. <input checked="" type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</li> <li>20. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4)</li> <li>21. <input checked="" type="checkbox"/> Other items or information: International Search Report (ISR)</li> </ol>					

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)		INTERNATIONAL APPLICATION NO. PCT/GB2003/002937		ATTORNEY DOCKET NO. 9052-212	
22. The following fees are submitted:  a) Basic national fee..... \$300.00. b) Examination fee..... \$200.00 c) Search fee..... \$500.00  <b>TOTAL OF ABOVE CALCULATIONS = \$1000.00</b>				<b>RECEIVED</b> <b>CENTRAL FAX CENTER</b> <b>JAN 23 2008</b>	
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.					
Total Sheets	Extra sheets	Number of each additional 50 or fraction thereof (round up to a whole number)	RATE		
29 -100+	-/50+	0	X \$250.00		
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).			\$		
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	
Total claims	27 - 20 =	7	x \$ 50.00	\$350.00	
Independent Claims	6 - 3 =	3	x \$200.00	\$600.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$360.00	\$	
<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$1,950.00	
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2				\$975.00	
<b>SUBTOTAL =</b>				\$975.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).			\$		
<b>TOTAL NATIONAL FEE =</b>				\$	
Fee for Recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +			\$		
<b>TOTAL FEES ENCLOSED =</b>				\$975.00	
				Amount to be refunded:	\$
				charged:	\$
a. <input checked="" type="checkbox"/> A check in the amount of \$975.00 to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. 50-0220 in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-0220. A duplicate copy of this sheet is enclosed. d. <input type="checkbox"/> Fees are to be charged to a credit card. <b>WARNING:</b> Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.					
<b>NOTE:</b> Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
<b>SEND ALL CORRESPONDENCE TO:</b>  Myers Bigel Sibley & Sajovec, P.A. P. O. Box 37428 Raleigh, North Carolina 27627 Telephone: (919) 854-1400 Facsimile: (919) 854-1401 Customer No. 20792					
 Shawna Cannon Lemon, Reg. #53,888 Date: January 6, 2005					
<b>CERTIFICATE OF EXPRESS MAILING</b> Express Mail Label No. EV 475664497 US Date of Deposit: January 6, 2005 I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Mail Stop PCT, P.O. Box 1450, Alexandria, VA 22313-1450  Susan E. Freedman Date of Signature: January 6, 2005					

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
15 January 2004 (15.01.2004)

PCT

(10) International Publication Number  
WO 2004/005333 A1

- (51) International Patent Classification<sup>7</sup>: C07K 14/18, A61K 31/13, G01N 33/68
- (21) International Application Number: PCT/GB2003/002937
- (22) International Filing Date: 7 July 2003 (07.07.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
0215617.2 8 July 2002 (08.07.2002) GB
- (71) Applicant (for all designated States except US): UNIVERSITY OF LEEDS [GB/GB]; Leeds LS2 9JT (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): ROWLANDS, David [GB/GB]; School of Biochemistry and Molecular Biology, University of Leeds, Leeds LS2 9JT (GB). GRIFFIN, Stephen [GB/GB]; School of Biochemistry and Molecular Biology, University of Leeds, Leeds LS2 9JT (GB).
- (54) Title: USE OF HEPATITIS C VIRUS (HCV) P7 PROTEIN
- (57) Abstract: The present invention relates to the use of hepatitis C virus (HCV) p7 protein, and particularly but not exclusively, to its use in rationalised drug design and as a screen for antiviral therapeutic agents.
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NL, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW); Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM); European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR); OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/005333 A1